Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AnGes (AJW) Stock Price & Analysis

AJW Stock Chart & Stats

€0.11€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.5€1€1.5€25 Oct7 Mar20 Oct27 May19 Nov20 Jan5 May
Day’s Range
EUR 0.11 - EUR 0.11
52-Week Range
EUR 0.11 - EUR 0.47
Previous Close
EUR 0.11
Volume
0
Average Volume (3M)
0
Market Cap
EUR 66.65M
Enterprise Value
EUR 19.10B
Total Cash (Recent Filing)
EUR 296.72M
Total Debt (Recent Filing)
EUR 723.78M
Price to Earnings (P/E)
―
Beta
0.39
Next Earnings
Nov 06, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue

Accelerating revenue indicates stronger commercialization or collaboration activity across the biotechnology portfolio. If this growth persists, it can broaden the company’s funding base, improve operating leverage, and provide a more durable path toward supporting development investment.

Low Leverage

Low leverage gives AnGes greater financial flexibility than a heavily indebted biotechnology company. The balance sheet is less exposed to mandatory interest and principal payments, allowing management to direct available resources toward research, regulatory work, and commercialization efforts.

Improving Cash Burn

Improvement in free cash flow burn suggests some progress in controlling the pace of cash consumption, even though cash flow remains negative. A sustained reduction in burn would extend financial runway and reduce the urgency of obtaining external funding to maintain operations.

Bears Say

Persistent Unprofitability

Persistent operating and net losses show that AnGes has not yet established a profitable earnings base. Continued losses can limit internally funded research and commercialization, while making future performance dependent on successful products, partnerships, or additional financing.

Ongoing Cash Burn

Deeply negative operating and free cash flow means the current business does not fund its own ongoing activities. This creates continuing reliance on external funding or balance-sheet resources, which can constrain strategic choices and raise the risk of dilution or financing pressure.

Eroding Balance Sheet

Declining equity and assets reduce the financial cushion available to absorb continued development losses. Even with low leverage, ongoing balance-sheet erosion can weaken funding flexibility, make long-term investment harder to sustain, and increase dependence on successful pipeline outcomes.

AJW FAQ

What was AnGes’s price range in the past 12 months?
AnGes lowest stock price was €0.11 and its highest was €0.47 in the past 12 months.
What is AnGes’s market cap?
AnGes’s market cap is €66.65M.
When is AnGes’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AnGes’s earnings last quarter?
AnGes released its earnings results on Aug 07, 2026. The company reported -€0.022 earnings per share for the quarter.
Is AnGes overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does AnGes pay dividends?
AnGes does not currently pay dividends.
What is AnGes’s EPS estimate?
AnGes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AnGes have?
AnGes has 405,197,240 shares outstanding.
What happened to AnGes’s price movement after its last earnings report?
AnGes reported an EPS of -€0.022 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AnGes?
Currently, no hedge funds are holding shares in DE:AJW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology